Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and treatments against a long ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.